Australia Health

AFT Pharmaceuticals (ASX:AFP) announced sustained double-digit revenue growth for the first half of FY27.

Aroa Biosurgery (ASX:ARX) released clinical trial results showing its Symphony biosaffold improved healing outcomes for patients with diabetic foot ulcers.

Dimerix (ASX:DXB) announced that its first patient completed a two-year open-label extension study, marking four continuous years of DMX-200 treatment.

Imugene (ASX:IMU) released clinical results showing a 71% overall response rate in seven evaluable patients enrolled in Cohort 3 of its azer-cel Phase 1b trial.

HealthCo Healthcare & Wellness REIT (ASX:HCW) has secured binding lease agreements for its 10 Healthscope hospitals.

CSL (ASX:CSL) signed an agreement with Alentis Therapeutics to co-develop and co-promote lixudebart in an upfront deal worth US$355 million.

Artrya (ASX:AYA) executed a five-year commercial agreement with Huntsville Hospital Health System featuring a minimum contracted value of US$0.5 million.

Island Pharmaceuticals (ASX:ILA) commenced manufacturing of its active pharmaceutical ingredient, Galidesivir, on Oct. 1.

TruScreen Group (ASX:TRU) announced that CEO Martin Dillon has resigned from his position for personal reasons, effective Oct. 31.

Optiscan Imaging (ASX:OIL) has lodged a 510(k) submission with the U.S. Food and Drug Administration for its InForm digital pathology device.

Syntara (ASX:SNT) has expanded its double-blind, placebo-controlled Phase 1b clinical study of its topical drug SNT-9465.

Talius Group (ASX:TAL) has entered into a binding commercial partnership with Health Generation to take its co-branded CareGen Intelligence platform to market.